Up to
0
people worldwide may have primary aldosteronism
0
do not know they do
0
could be surgically cured
0
could be medically treated
Although it affects millions of hypertensives, primary aldosteronism is mistakenly considered “rare.”
Understanding of the disease remains fragmented, and it is seldom diagnosed and treated.
Although it affects millions of hypertensives, primary aldosteronism is mistakenly considered “rare.” Understanding of the disease remains fragmented, and it is seldom adequately diagnosed and treated.
Welcome to the Primary Aldosteronism Foundation
A Patient-Driven Initiative Dedicated to Advocacy, Education, and Research
We are a patient initiative created to raise awareness of the prevalence of primary aldosteronism, encourage timely diagnosis and treatment, foster accelerated research, and facilitate patient collaboration.
We help those who have, or suspect they have primary aldosteronism, navigate the road to accurate diagnosis, obtain adequate and effective treatment, stay abreast of relevant medical advances, and optimize care.
We serve the primary aldosteronism community worldwide and are headquartered in the US state of Arizona.
Whether you or someone you know have high blood pressure that is long-standing and/or difficult to control, help us support the development of adequate responses to primary aldosteronism by signing the Foundation’s Open Letter.
We serve the primary aldosteronism community worldwide and are headquartered in the US state of Arizona.
Whether you or someone you know have hypertension that is long-standing and/or difficult to control, help us support the development of adequate responses to primary aldosteronism by signing the Foundation’s Open Letter.
Find a PA Expert
International specialists treating primary aldosteronism.
Find a Center of Excellence
Dedicated PA departments at
medical centers worldwide.
medical centers worldwide.
Find Support
Patient support groups and other resources available online.
It Takes a Village
Each contribution helps to make a difference.
Next-Generation PA Drugs
Clinical research studies are recruiting PA participants.
PA and COVID-19
Underlying conditions like PA affect disease outcome.